知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.024 秒)

    HIV-1 GP120 MINI V3 LOOP AND USES THEREOF
    3.
    发明申请
    HIV-1 GP120 MINI V3 LOOP AND USES THEREOF 有权
    HIV-1 GP120 MINI V3环路及其用途

    公开(公告)号：US20140302081A1

    公开(公告)日：2014-10-09

    申请号：US14251070

    申请日：2014-04-11

    申请人： The Scripps Research Institute

    发明人： Ian A. Wilson ,  Robyn L. Stanfield ,  Robert Pejchal

    IPC分类号： A61K39/21 ,  G01N33/569

    CPC分类号： A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C07K16/1063 ,  C07K16/44 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2740/15034 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56983 ,  G01N33/56988

    摘要： The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.

    摘要翻译： 本发明涉及免疫原性HIV-1 gp120 mini V3环，其是全长gp120 V3环的截短形式，其可用于结合识别碳水化合物部分的抗体。 本发明还涉及通过结晶学技术测定的广泛中和抗体与糖基化gp120外部结构域的复合物的结构，以及确认糖基化gp120外部结构域具有功能相关构象以及确定关键 糖基化gp120外部结构域上的残基，及其用途及其化合物和组合物。 此外，本发明还涉及与广泛中和抗体结合的其它肽和模拟肽。

    METHODS AND COMPOSITIONS RELATED TO MODULATORS OF EUKARYOTIC CELLS
    5.
    发明申请
    METHODS AND COMPOSITIONS RELATED TO MODULATORS OF EUKARYOTIC CELLS 有权
    与真核细胞调节剂相关的方法和组合物

    公开(公告)号：US20150316561A1

    公开(公告)日：2015-11-05

    申请号：US14424663

    申请日：2013-08-16

    申请人： THE SCRIPPS RESEARCH INSTITUTE

    发明人： Hongkai Zhang ,  Ian A. Wilson ,  Richard A. Lerner

    IPC分类号： G01N33/68

    CPC分类号： C07K16/2863 ,  C07K14/71 ,  C07K14/7153 ,  C07K16/2839 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30 ,  C40B30/06 ,  G01N33/6845 ,  G01N33/6854 ,  G01N33/746

    摘要： Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.

    摘要翻译： 通过在真核细胞内表达潜在激动剂的组合文库，然后直接选择靶分子的激动剂来鉴定真核细胞的蛋白质调节剂的方法。 一些方法涉及共培养表达潜在激动剂和第二细胞的组合文库的细胞，然后选择调节第二细胞中表型或期望细胞应答的药剂。 优选地，激动剂是引入起始细胞中并在起始细胞中表达的抗体，例如激动剂抗EpoR，抗TpoR或G-CSFR抗体。 还公开了从组合抗体文库中选择可以调节细胞表型的双特异性抗体的方法。

    Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines
    8.
    发明申请
    Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines 有权

    公开(公告)号：US20210139543A1

    公开(公告)日：2021-05-13

    申请号：US17087704

    申请日：2020-11-03

    申请人： The Scripps Research Institute

    发明人： Linling He ,  Jiang Zhu ,  Ian A. Wilson

    IPC分类号： C07K14/005 ,  C12N7/00 ,  A61K39/215 ,  A61P31/14

    摘要： The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.